$23.66
+0.67
(+2.91%)▲
2.87%
Downside
Day's Volatility :2.87%
Upside
0.0%
20.08%
Downside
52 Weeks Volatility :57.11%
Upside
46.34%
Period | Fulgent Genetics Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 14.38% | 6.5% | 0.0% |
6 Months | -10.2% | 7.1% | 0.0% |
1 Year | -41.23% | 9.8% | 0.0% |
3 Years | -75.02% | 14.2% | -20.2% |
Market Capitalization | 691.0M |
Book Value | $37.8 |
Earnings Per Share (EPS) | -5.56 |
PEG Ratio | 1.32 |
Wall Street Target Price | 26.67 |
Profit Margin | -57.72% |
Operating Margin TTM | -33.8% |
Return On Assets TTM | -3.34% |
Return On Equity TTM | -14.46% |
Revenue TTM | 287.5M |
Revenue Per Share TTM | 9.64 |
Quarterly Revenue Growth YOY | -2.5% |
Gross Profit TTM | 366.9M |
EBITDA | -43.7M |
Diluted Eps TTM | -5.56 |
Quarterly Earnings Growth YOY | -0.99 |
EPS Estimate Current Year | -0.92 |
EPS Estimate Next Year | -0.85 |
EPS Estimate Current Quarter | -0.32 |
EPS Estimate Next Quarter | -0.28 |
What analysts predicted
Upside of 12.72%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 21.4M | ↑ 14.03% |
Net Income | -4.5M | ↑ 68.7% |
Net Profit Margin | -21.02% | ↓ 6.81% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 32.5M | ↑ 52.31% |
Net Income | 366.0K | ↓ 108.15% |
Net Profit Margin | 1.13% | ↑ 22.15% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 421.7M | ↑ 1196.46% |
Net Income | 214.3M | ↑ 58454.64% |
Net Profit Margin | 50.82% | ↑ 49.69% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 992.6M | ↑ 135.37% |
Net Income | 104.3M | ↓ 51.31% |
Net Profit Margin | 10.51% | ↓ 40.31% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 619.0M | ↓ 37.64% |
Net Income | 143.4M | ↑ 37.44% |
Net Profit Margin | 23.17% | ↑ 12.66% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 289.2M | ↓ 53.27% |
Net Income | -167.8M | ↓ 217.03% |
Net Profit Margin | -58.03% | ↓ 81.2% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 67.7M | ↓ 35.92% |
Net Income | -24.1M | ↓ 1892.7% |
Net Profit Margin | -35.56% | ↓ 36.83% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 66.2M | ↓ 2.27% |
Net Income | -15.8M | ↓ 34.17% |
Net Profit Margin | -23.95% | ↑ 11.61% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 67.9M | ↑ 2.55% |
Net Income | -11.2M | ↓ 29.15% |
Net Profit Margin | -16.55% | ↑ 7.4% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 84.7M | ↑ 24.81% |
Net Income | -13.1M | ↑ 16.72% |
Net Profit Margin | -15.48% | ↑ 1.07% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 70.5M | ↓ 16.75% |
Net Income | -128.1M | ↑ 877.71% |
Net Profit Margin | -181.76% | ↓ 166.28% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 64.5M | ↓ 8.54% |
Net Income | -13.5M | ↓ 89.5% |
Net Profit Margin | -20.88% | ↑ 160.88% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 55.0M | ↓ 3.4% |
Total Liabilities | 2.7M | ↓ 6.15% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 88.8M | ↑ 61.33% |
Total Liabilities | 6.0M | ↑ 117.81% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 700.5M | ↑ 689.2% |
Total Liabilities | 131.1M | ↑ 2092.24% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 1.3B | ↑ 82.55% |
Total Liabilities | 112.8M | ↓ 13.91% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 1.4B | ↑ 8.39% |
Total Liabilities | 116.2M | ↑ 2.96% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 1.3B | ↓ 8.15% |
Total Liabilities | 139.8M | ↑ 20.35% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.4B | ↓ 1.4% |
Total Liabilities | 116.2M | ↓ 6.6% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.4B | ↓ 0.67% |
Total Liabilities | 107.8M | ↓ 7.17% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.4B | ↓ 1.61% |
Total Liabilities | 91.3M | ↓ 15.39% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.4B | ↑ 0.28% |
Total Liabilities | 96.6M | ↑ 5.82% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.3B | ↓ 6.28% |
Total Liabilities | 139.8M | ↑ 44.8% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 1.2B | ↓ 3.4% |
Total Liabilities | 103.2M | ↓ 26.16% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -675.0K | ↓ 150.71% |
Investing Cash Flow | 950.0K | ↓ 146.36% |
Financing Cash Flow | 15.0K | ↓ 101.95% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 5.5M | ↓ 917.33% |
Investing Cash Flow | -29.0M | ↓ 3157.47% |
Financing Cash Flow | 28.8M | ↑ 191733.33% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 140.6M | ↑ 2448.99% |
Investing Cash Flow | -326.4M | ↑ 1023.87% |
Financing Cash Flow | 261.3M | ↑ 807.91% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 534.3M | ↑ 279.9% |
Investing Cash Flow | -546.5M | ↑ 67.43% |
Financing Cash Flow | 85.4M | ↓ 67.31% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 253.5M | ↓ 52.55% |
Investing Cash Flow | -261.3M | ↓ 52.19% |
Financing Cash Flow | -77.1M | ↓ 190.33% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 33.2M | ↑ 59.83% |
Investing Cash Flow | -92.6M | ↓ 309.08% |
Financing Cash Flow | -29.6M | ↓ 16.55% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -7.9M | ↓ 123.81% |
Investing Cash Flow | -4.4M | ↓ 95.3% |
Financing Cash Flow | -1.1M | ↓ 96.28% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 9.7M | ↓ 223.14% |
Investing Cash Flow | -1.1M | ↓ 74.83% |
Financing Cash Flow | -16.3M | ↑ 1376.75% |
Sell
Neutral
Buy
Fulgent Genetics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Fulgent Genetics Inc | 12.92% | -10.2% | -41.23% | -75.02% | 267.84% |
![]() Idexx Laboratories, Inc. | -3.67% | -10.34% | -15.37% | -31.35% | 65.77% |
![]() Agilent Technologies Inc. | 1.42% | 3.05% | 5.07% | -10.16% | 94.22% |
![]() Thermo Fisher Scientific, Inc. | 6.51% | 8.62% | 3.5% | 12.36% | 106.99% |
![]() Danaher Corp. | 6.51% | 15.92% | 1.97% | -6.92% | 89.83% |
![]() Iqvia Holdings Inc. | 10.0% | 7.5% | 0.14% | -6.07% | 45.29% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Fulgent Genetics Inc | 7.49 | NA | 1.32 | -0.92 | -0.14 | -0.03 | NA | 37.8 |
![]() Idexx Laboratories, Inc. | 45.67 | 45.67 | 4.75 | 11.06 | 0.72 | 0.23 | NA | 18.93 |
![]() Agilent Technologies Inc. | 31.63 | 31.63 | 2.7 | 5.2 | 0.21 | 0.08 | 0.01 | 21.31 |
![]() Thermo Fisher Scientific, Inc. | 35.72 | 35.72 | 2.81 | 21.71 | 0.14 | 0.05 | 0.0 | 120.87 |
![]() Danaher Corp. | 48.76 | 48.76 | 3.13 | 6.99 | 0.08 | 0.04 | 0.0 | 68.92 |
![]() Iqvia Holdings Inc. | 30.13 | 30.13 | 1.33 | 11.19 | 0.23 | 0.05 | NA | 36.83 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Fulgent Genetics Inc | Buy | $691.0M | 267.84% | 7.49 | -57.72% |
![]() Idexx Laboratories, Inc. | Buy | $38.8B | 65.77% | 45.67 | 23.26% |
![]() Agilent Technologies Inc. | Buy | $38.9B | 94.22% | 31.63 | 18.84% |
![]() Thermo Fisher Scientific, Inc. | Buy | $219.4B | 106.99% | 35.72 | 14.2% |
![]() Danaher Corp. | Buy | $191.9B | 89.83% | 48.76 | 17.83% |
![]() Iqvia Holdings Inc. | Buy | $42.3B | 45.29% | 30.13 | 9.39% |
Insights on Fulgent Genetics Inc
Revenue is down for the last 3 quarters, 84.68M → 64.48M (in $), with an average decrease of 12.6% per quarter
Netprofit is up for the last 2 quarters, -128.14M → -13.46M (in $), with an average increase of 851.9% per quarter
In the last 1 year, Agilent Technologies Inc. has given 5.1% return, outperforming this stock by 46.3%
In the last 3 years, Fulgent Genetics Inc has experienced a drawdown of -75.0%, however Thermo Fisher Scientific, Inc. resisted the overall trend and outperformed by 64.8%
BlackRock Inc
Vanguard Group Inc
Dimensional Fund Advisors, Inc.
State Street Corporation
Park West Asset Management LLC
Millennium Management LLC
mission developing flexible and affordable genetic testing that improves the everyday lives of those around us. founded in 2011, fulgent began with two simple ideas; flexibility and affordability. today, we strive to create the most effective and wide ranging tests on the market. all of this is done in the pursuit of bettering the everyday lives of our customers. we shine brightest when meaningful relationships, passion, and purpose come together. why fulgent? we are committed to working side-by-side with every one of our clients. this is essential to a strong and successful relationship and is our core way of doing business. we have collaborated with some of the top clinicians in our field who have assisted us in creating our panels, report formatting, and improvements to our website. our approach has always been simple: provide testing based on the specific needs of clinicians and their patients. customer support our support philosophy has always been simple: answer our client's ques
Organization | Fulgent Genetics Inc |
Employees | 1184 |
CEO | Mr. Ming Hsieh |
Industry | Health Services |
A Spac I Acquisition Corp
$23.66
+2.91%
Keyarch Acquisition Corp
$23.66
+2.91%
Connexa Sports Technologies Inc
$23.66
+2.91%
Us Value Etf
$23.66
+2.91%
First Wave Biopharma Inc
$23.66
+2.91%
Global X Msci Next Emerging
$23.66
+2.91%
Fat Projects Acquisition Corp
$23.66
+2.91%
Capital Link Global Fintech
$23.66
+2.91%
Applied Uv Inc
$23.66
+2.91%